|
Liver neoplasms
|
0.280 |
Biomarker
|
group |
BEFREE |
In this work, we characterized the effect of Hepc produced by hepatoma cells on iron absorption by intestinal cells.
|
16629180 |
2006 |
|
Liver neoplasms
|
0.280 |
AlteredExpression
|
group |
BEFREE |
To address this issue, GFP was fused to the C-terminus of hepcidin and the chimeric hepcidin-GFP protein was expressed in hepatoma Huh7 cells.
|
23665013 |
2013 |
|
Liver neoplasms
|
0.280 |
AlteredExpression
|
group |
BEFREE |
We analyzed human hepatoma (HepG2) cells and mouse primary hepatocytes to study transcriptional control of Hamp (the gene that encodes Hepcidin) in response to gluconeogenic stimuli using small interfering RNA, luciferase promoter, and chromatin immunoprecipitation analyses.
|
24361124 |
2014 |
|
Liver neoplasms
|
0.280 |
AlteredExpression
|
group |
BEFREE |
Hepcidin expression was also measured in human hepatoma HepG2 cells following incubation with thalassemic sera.
|
16339657 |
2005 |
|
Liver neoplasms
|
0.280 |
AlteredExpression
|
group |
BEFREE |
However, in vitro studies with hepatoma cell lines often show an inverse relationship between iron status and hepcidin expression.
|
20576915 |
2010 |
|
Liver neoplasms
|
0.280 |
Biomarker
|
group |
BEFREE |
Hepcidin generated by hepatoma cells inhibits iron export from co-cultured THP1 monocytes.
|
16460831 |
2006 |
|
Liver neoplasms
|
0.280 |
Biomarker
|
group |
RGD |
Hepcidin and DNA promoter methylation in hepatocellular carcinoma.
|
29235098 |
2018 |
|
Liver neoplasms
|
0.280 |
AlteredExpression
|
group |
BEFREE |
In this study, we investigated the effect of changes in the pH of the microenvironment on hepcidin expression in human hepatoma and leukemia cell lines.
|
23179904 |
2012 |
|
Liver neoplasms
|
0.280 |
Biomarker
|
group |
BEFREE |
We have measured secretion of hepcidin by primary macrophages and the hepatoma cell line HepG2 stimulated with IL-10, IL-6 and Plasmodium falciparum-infected erythrocytes.
|
24520384 |
2014 |
|
Diabetes Mellitus
|
0.190 |
Biomarker
|
group |
HPO |
|
|
|
|
Diabetes Mellitus
|
0.190 |
Biomarker
|
group |
BEFREE |
ROC analysis revealed that ferritin, hepcidin and transferrin are markers that can distinguish PTB-DM from DM individuals.
|
29523313 |
2018 |
|
Diabetes Mellitus
|
0.190 |
Biomarker
|
group |
BEFREE |
Besides, hepcidin concentrations have been linked to inflammatory cytokines, matriptase 2, and chronic hepatitis C infection, which have in turn been reported to be associated with diabetes by several approaches.
|
29136618 |
2017 |
|
Diabetes Mellitus
|
0.190 |
Biomarker
|
group |
BEFREE |
Hepcidin, the iron hormone, seems to hold a central pathogenic place in hemochromatosis, similar to insulin in diabetes: Genetically determined lack of hepcidin synthesis or activity may cause the disease.
|
16848707 |
2006 |
|
Diabetes Mellitus
|
0.190 |
Biomarker
|
group |
BEFREE |
Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients.
|
31296086 |
2019 |
|
Diabetes Mellitus
|
0.190 |
Biomarker
|
group |
BEFREE |
The role of hepcidin in the pathogenesis of hemochromatosis reveals its similarities to endocrine diseases such as diabetes and indicates new approaches to diagnosis and management of this common disorder in iron metabolism.
|
20542038 |
2010 |
|
Diabetes Mellitus
|
0.190 |
AlteredExpression
|
group |
BEFREE |
Hepcidin levels were lower in persons with prediabetes compared to control, while persons with diabetes on insulin therapy had higher values than those with prediabetes (p = 0,00001).
|
28841871 |
2017 |
|
Diabetes Mellitus
|
0.190 |
Biomarker
|
group |
BEFREE |
Recent data suggest that insulin therapy and probably other diabetes drugs can influence hepcidin production, thus influencing the iron load in cells.
|
28662967 |
2018 |
|
Diabetes Mellitus
|
0.190 |
AlteredExpression
|
group |
BEFREE |
The presence of diabetes or NASH did not modify the hepcidin expression levels in liver and adipose tissue.
|
16952548 |
2006 |
|
Diabetes Mellitus
|
0.190 |
Biomarker
|
group |
BEFREE |
The interplay between LBP, IL-6, hepcidin, and ferritin characterizes metabolic derangements after acute pancreatitis and may play a role in the pathogenesis of new-onset diabetes after pancreatitis.
|
28982582 |
2018 |
|
Cardiomyopathies
|
0.110 |
GeneticVariation
|
group |
BEFREE |
HJV and HAMP HH are phenotypically and clinically very similar and have the most severe presentation, with cardiomyopathy and hypogonadism being particularly prevalent findings.
|
29743178 |
2018 |
|
Cardiomyopathies
|
0.110 |
Biomarker
|
group |
HPO |
|
|
|
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results demonstrate the key role of the convertases Furin, PACE4, PC5 and/or PC7 in the generation and secretion of active hepcidin and suggest that the control of hepcidin processing as a potential therapeutic/diagnostic strategy in hepcidin-related disorders such as haemochromatosis, inflammatory diseases, anaemia and cancer.
|
18664504 |
2008 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We analyzed liver samples from patients undergoing hepatic surgery for cancer or receiving liver transplants and analyzed correlations between clinical parameters and liver hepcidin mRNA and urinary hepcidin concentrations.
|
15797999 |
2005 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results demonstrate that a commonly used anti-hypertensive drug, spironolactone, which is prescribed for the treatment of heart failure, acne and female hirsutism, as well as imatinib, a first-line, lifelong therapeutic option for some frequent cancer types suppress hepcidin expression in cultured cells and in mice.
|
28385785 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In tumor cells, iron metabolism changes by several mechanisms, such as regulating the growth of tumor cells by transferrin, accelerating the uptake of iron by the overexpressions of transferrin receptors 1 and 2 (TfR1 and TfR2), synthesizing or secreting ferritin by some malignant tumor cells, and upregulating the level of hepcidin in patients with cancer.
|
20346225 |
2010 |